Every material Form 8-K CorMedix Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 8, 2026, CorMedix agreed to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash, 14,583,333 new CorMedix common shares, earn-out payments of up to $55 million, and royalties. CorMedix entered into a $150 million senior secured term loan with Pharmakon Advisors to help fund the deal, with $75 million expected to be drawn at closing. The share issuance will dilute existing CorMedix shareholders, and closing is expected in the first quarter of 2027, subject to Heron stockholder approval and regulatory clearance.
Upfront consideration is $145.0 million in cash, subject to adjustments, plus 14,583,333 shares of CorMedix common stock.
Earn-outs of up to $55 million are tied to 2028 ZYNRELEF net sales, with a 5.0% royalty on certain product sales above $25.0 million a year in 2027 through 2029.
CorMedix entered into a $150 million Pharmakon term loan and expects to draw $75 million at closing.
Closing is expected in the first quarter of 2027, subject to Heron stockholder approval and HSR clearance; Heron owes a $4.0 million termination fee in certain cases.
CorMedix said unaudited cash and cash equivalents were about $355 million as of September 30, 2026, and reaffirmed its full-year 2026 total revenue guidance. The company also said CMS's final rule sets a $8.32 per session DefenCath Add-on for the first quarter of 2027, and it expects the 2027 average Add-on rate to exceed twice the current $2.37 rate.
Unaudited cash and cash equivalents of about $355 million as of September 30, 2026
2026 total revenue guidance of $325 million to $345 million reaffirmed, unchanged from August 2026
CMS set a DefenCath post-TDAPA Add-on of $8.32 per dialysis session for Q1 2027, versus $2.37 in effect for Q3 and Q4 2026
Company expects the Add-on to decline in Q2 2027 versus Q1, then rise in Q3 and/or Q4 2027; conference call set for November 12, 2026
The FDA accepted for filing a supplemental New Drug Application for REZZAYO (rezafungin) for the prophylaxis of invasive fungal disease and granted Priority Review, with a PDUFA target action date in Q1 2027. The application was submitted by partner Mundipharma and is supported by the Phase III ReSPECT study. Acceptance does not assure approval, and CorMedix is targeting promotional efforts beginning in H2 2027 if the indication is approved.
FDA accepted the sNDA for filing and granted Priority Review
PDUFA target action date is in Q1 2027
Application was submitted by Mundipharma, CorMedix's global development partner
If approved, CorMedix is targeting promotional efforts beginning in H2 2027
CorMedix reported second-quarter 2026 revenue of $101.9 million, up from $39.7 million a year earlier, and net income of $26.0 million, up from $19.8 million. The company kept its full-year 2026 revenue guidance of $325 million to $345 million and raised its adjusted EBITDA guidance to $125 million to $140 million, which matters to shareholders because it signals stronger expected profitability.
Q2 2026 revenue of $101.9 million: $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio
Q2 2026 net income of $26.0 million, or $0.33 basic and $0.29 diluted per share, versus $19.8 million in Q2 2025
Adjusted EBITDA of $58.7 million in Q2 2026 versus $22.4 million a year earlier; full-year adjusted EBITDA guidance raised to $125 million to $140 million
Full-year 2026 revenue guidance maintained at $325 million to $345 million; cash and short-term investments of $256.7 million at June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CorMedix Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →